Skip to main content

2018

Press release

Pharming announces FDA Acceptance for Review of Supplemental Biologics License Application for RUCONEST® for Prophylaxis of Hereditary Angioedema Attacks

Pharming Group N.V. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Pharming’s supplemental Biologics License Application (sBLA) for RUCONEST® [Recombinant Human C1 Esterase Inhibitor/ conestat alfa] for routine prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema (HAE).

Read more

2017

Press release

Pharming Submits Supplemental Biologics License Application to FDA for RUCONEST® for Prophylaxis of Hereditary Angioedema Attacks

Pharming Group N.V. today announced that it has submitted a supplemental Biologics License Application (BLA) to the U.S. Food and Drug Administration (“FDA”) for RUCONEST® [Recombinant Human C1 Esterase Inhibitor/ conestat alfa] for routine prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema (“HAE”).

Read more

Filter

Cookies: This website uses cookies Check the cookies page for more information Accept Decline